HALO
Halozyme Therapeutics Inc.

4,924
Mkt Cap
$7.85B
Volume
46.00
52W High
$82.22
52W Low
$47.50
PE Ratio
26.68
HALO Fundamentals
Price
$63.56
Prev Close
$66.48
Open
$65.38
50D MA
$72.35
Beta
0.72
Avg. Volume
2.25M
EPS (Annual)
$2.56
P/B
160.41
Rev/Employee
$3.3M
$10,373.12
Loading...
Loading...
News
all
press releases
Halozyme Appoints David Ramsay As Interim CFO
(RTTNews) - Halozyme Therapeutics Inc. (HALO), on Thursday, appointed David Ramsay as interim chief financial officer, effective March 23...
Nasdaq News: Markets·23h ago
News Placeholder
More News
News Placeholder
Halozyme Appoints David Ramsay as Interim Chief Financial Officer
Halozyme Appoints David Ramsay as Interim Chief Financial Officer Halozyme Appoints David Ramsay as Interim Chief Financial Officer PR Newswire SAN DIEGO, March 12, 2026 SAN DIEGO, March 12, 2026...
PR Newswire·23h ago
News Placeholder
Capital Fund Management S.A. Has $15.60 Million Stake in Halozyme Therapeutics, Inc. $HALO
Capital Fund Management S.A. grew its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 97.1% during the third quarter, according to the company in its most recent disclosure...
MarketBeat·1d ago
News Placeholder
Insider Selling: Cortney Caudill Unloads $1.96M Of Halozyme Therapeutics Stock
read more...
Benzinga·2d ago
News Placeholder
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) COO Sells 8,857 Shares of Stock
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) COO Cortney Caudill sold 8,857 shares of Halozyme Therapeutics stock in a transaction that occurred on Tuesday, March 10th. The stock was...
MarketBeat·2d ago
News Placeholder
Halozyme Therapeutics, Inc. $HALO Shares Purchased by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP lifted its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 3.2% during the 3rd quarter, according to its most recent filing with the Securities and...
MarketBeat·2d ago
News Placeholder
Halozyme Therapeutics (NASDAQ:HALO) COO Cortney Caudill Sells 8,857 Shares
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) COO Cortney Caudill sold 8,857 shares of the company's stock in a transaction on Tuesday, March 10th. The stock was sold at an average...
MarketBeat·2d ago
News Placeholder
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) COO Sells 20,000 Shares of Stock
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) COO Cortney Caudill sold 20,000 shares of the firm's stock in a transaction dated Monday, March 9th. The stock was sold at an average price...
MarketBeat·2d ago
News Placeholder
DLD Asset Management LP Has $2.20 Billion Position in Halozyme Therapeutics, Inc. $HALO
DLD Asset Management LP raised its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 20.0% during the third quarter, according to the company in its most recent 13F filing with...
MarketBeat·4d ago
News Placeholder
Victory Capital Management Inc. Sells 46,430 Shares of Halozyme Therapeutics, Inc. $HALO
Victory Capital Management Inc. trimmed its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 6.9% during the third quarter, according to its most recent 13F filing with the...
MarketBeat·5d ago
<
1
2
...
>

Latest HALO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.